Zynerba Pharmaceuticals Inc (ZYNE) Expected to Post Earnings of -$0.69 Per Share
Wall Street analysts expect Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) to announce earnings per share of ($0.69) for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Zynerba Pharmaceuticals’ earnings. Zynerba Pharmaceuticals reported earnings per share of ($0.63) in the same quarter last year, which would suggest a negative year over year growth rate of 9.5%. The company is expected to announce its next earnings results on Tuesday, November 13th.
According to Zacks, analysts expect that Zynerba Pharmaceuticals will report full-year earnings of ($3.13) per share for the current fiscal year, with EPS estimates ranging from ($3.18) to ($3.06). For the next fiscal year, analysts forecast that the business will post earnings of ($2.61) per share, with EPS estimates ranging from ($2.68) to ($2.57). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that that provide coverage for Zynerba Pharmaceuticals.
Zynerba Pharmaceuticals (NASDAQ:ZYNE) last posted its earnings results on Thursday, August 2nd. The company reported ($0.89) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.77) by ($0.12).
ZYNE traded up $0.44 on Tuesday, hitting $7.63. The company had a trading volume of 15,734 shares, compared to its average volume of 406,728. Zynerba Pharmaceuticals has a 1-year low of $5.59 and a 1-year high of $15.14. The firm has a market cap of $143.81 million, a P/E ratio of -3.11 and a beta of 4.52.
In other Zynerba Pharmaceuticals news, Director John P. Butler purchased 5,000 shares of the company’s stock in a transaction on Wednesday, August 22nd. The shares were bought at an average cost of $6.43 per share, with a total value of $32,150.00. Following the transaction, the director now directly owns 5,000 shares in the company, valued at approximately $32,150. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO James E. Fickenscher purchased 8,518 shares of the company’s stock in a transaction on Monday, August 6th. The stock was acquired at an average cost of $5.97 per share, for a total transaction of $50,852.46. Following the completion of the transaction, the chief financial officer now owns 20,718 shares in the company, valued at $123,686.46. The disclosure for this purchase can be found here. Over the last 90 days, insiders purchased 32,318 shares of company stock valued at $194,404. Corporate insiders own 12.67% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of ZYNE. Millennium Management LLC increased its position in Zynerba Pharmaceuticals by 116.0% in the 2nd quarter. Millennium Management LLC now owns 224,511 shares of the company’s stock worth $2,187,000 after buying an additional 120,570 shares during the period. Paloma Partners Management Co bought a new stake in shares of Zynerba Pharmaceuticals during the second quarter valued at approximately $493,000. BlackRock Inc. increased its position in shares of Zynerba Pharmaceuticals by 5.4% during the first quarter. BlackRock Inc. now owns 715,185 shares of the company’s stock valued at $6,216,000 after purchasing an additional 36,488 shares during the period. LMR Partners LLP bought a new stake in shares of Zynerba Pharmaceuticals during the second quarter valued at approximately $312,000. Finally, Pennsylvania Trust Co increased its position in shares of Zynerba Pharmaceuticals by 17.4% during the third quarter. Pennsylvania Trust Co now owns 202,100 shares of the company’s stock valued at $1,649,000 after purchasing an additional 30,000 shares during the period. 14.22% of the stock is currently owned by institutional investors.
Zynerba Pharmaceuticals Company Profile
Zynerba Pharmaceuticals, Inc operates as a clinical stage specialty pharmaceutical company. The company focuses on developing and commercializing pharmaceutically-produced transdermal cannabinoid treatments for rare or near-rare neuropsychiatric disorders. Its product candidates include ZYN002, which completed Phase II clinical trial for pediatric and adolescent patients with fragile X syndrome, pediatric and adolescent patients with developmental and epileptic encephalopathies, and adult patients with refractory epileptic focal seizures; and ZYN001 that is in Phase I clinical trial to treat Tourette syndrome.
Further Reading: What is Considered a Good Return on Equity (ROE)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zynerba Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.